Aprogen Biologics Inc. announced a private placement to issue 33,039,648 common shares at an issue price of KRW 908 per share for the gross proceeds of KRW 30,000,000,384 on July 4, 2024. The transaction will include participation from new returning Aprogen Medicines. The transaction has been approved by shareholders of company, restricted to a hold period and is expected to close on August 14, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,047 KRW | -5.68% | -19.46% | -63.90% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,497 KRW | -4.47% | +0.94% | 28Cr | ||
1,047 KRW | -5.68% | -19.46% | 9.94Cr | ||
1st Jan change | Capi. | |
---|---|---|
-63.90% | 9.94Cr | |
+61.53% | 85TCr | |
+33.58% | 63TCr | |
-3.66% | 36TCr | |
+15.06% | 32TCr | |
+9.18% | 30TCr | |
+12.02% | 23TCr | |
+16.19% | 23TCr | |
+15.67% | 18TCr | |
+2.47% | 17TCr |
- Stock Market
- Equities
- A003060 Stock
- News Aprogen Biologics Inc.
- Aprogen Biologics Inc. announced that it expects to receive KRW 30.000000384 billion in funding from Aprogen Medicines Inc.